Tags : WW Rights


Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage

Shots: Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer Accordingly, Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing, an oral androgen inhibitor, for prostate cancer Click here […]Read More